Rare diseases in Malaysia: The hidden crisis few are talking about
Malaysia faces significant challenges in treating rare diseases, including limited resources, high treatment costs, and a shortage of specialised healthcare professionals.
Collaboration among healthcare providers, government, and patient groups is crucial for improving care and advancing treatment options for rare disease patients.
KUALA LUMPUR, April 17 — Rare diseases affect only a small number of people, but for those living with them in Malaysia, the struggle is real and often overlooked.
Although rare diseases affect fewer than one in 4,000 people, these conditions are enigmatic and often not fully understood.
As of 2020, Malaysia has documented 491 rare diseases. However, a thorough understanding remains elusive due to limited epidemiological data.
Here's what we know about the rare disease landscape in Malaysia.
Understanding rare diseases
Rare diseases, by definition, are health conditions that affect a small fraction of the population.
They often present with various symptoms that not only differ from one disease to another but also within the same condition.
The rarity and diversity of these diseases create significant challenges in diagnosis, treatment, and management.
While each rare disease is uncommon, together they affect many people around the world — including in Malaysia.
How rare diseases affect Malaysians
According to Malaysia Rare Disease Society president Nadiah Hanim Abdul Latif, it is estimated that one million Malaysians are living with a rare disease.
She said the estimation aligns with the 2020 evidence-based analysis of the Orphanet database, suggesting that 3.5 per cent to 5.9 per cent of the global population is affected by rare conditions.
However, Nadiah said the figures are just estimates because Malaysia lacks a national patient registry, making the exact number of those impacted unclear.
Despite these challenges, Nadiah said the Malaysian rare disease ecosystem now benefits from enhanced collaboration among healthcare providers, government agencies, policymakers, industry, and patient groups.
'Our efforts have not only strengthened within Malaysia but have extended to regional and international levels.
'Leaders from the 20 rare disease organisations in Malaysia are taking active roles in international rare disease forums,' she added.
Why rare diseases need urgent attention
According to Nadiah, addressing rare disease treatment in Malaysia is critical due to significant healthcare system challenges.
'Although each rare disease is uncommon individually, collectively they affect a substantial population, necessitating management approaches akin to non-communicable diseases,' she said.
Moving forward, she said, a proactive approach, focusing on early diagnosis and a lifelong health plan, can mitigate healthcare costs and should be viewed as a health investment.
In contrast, she added that relying on reactive measures escalates costs and increases disability and suffering.
'Rare diseases are not just a health issue. They also place a heavy burden on national resources,' she said.
'Managing these conditions effectively could position Malaysia as a regional hub for rare disease expertise, whereas neglect could lead to an ageing nation with limited resources and increasing unmet needs,' she added.
Gaps in treatment and care
Presently, Malaysia's resources for treating rare diseases remain insufficient, said Nadiah.
According to her, developing orphan drugs requires major investment in research and facilities.
'Globally, only five per cent of rare diseases have treatments,' she said. 'The remaining 95 per cent rely on symptom management to maintain their quality of life.'
'Meanwhile, for those with treatments available, affordability remains a critical hurdle,' she added.
For patients depending on symptom management, Nadiah said the scarcity of specialised healthcare professionals is a major challenge.
'Currently, only 14 geneticists are serving the entire country, spread across six genetic clinics in various government hospitals,' she said.
'Addressing these gaps is crucial to improving access to specialised care and advancing treatment options for rare disease patients in Malaysia,' she added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
09-07-2025
- Yahoo
IHH Healthcare pursues expansion in Indonesia and Vietnam
Malaysian hospital operator IHH Healthcare has set its sights on expansion into Indonesia and Vietnam to boost its scale amid escalating care expenses in the region, as reported by Bloomberg. Indonesia's healthcare reforms and relaxed foreign ownership rules, along with Vietnam's burgeoning market present new opportunities for growth, stated IHH Healthcare CEO Prem Kumar Nair. Prem Kumar Nair said: 'We get a lot of patients from Vietnam into our Singapore operations.' IHH runs over 80 hospitals across ten countries, encompassing Singapore, India, and China. The hospital operator is on an acquisition spree, having recently added Island Hospital in Malaysia to its portfolio in 2024. Its subsidiaries, Acibadem in Turkey and Fortis Healthcare in India have also expanded by purchasing additional hospitals in the past two years. IHH has a market capitalisation of $14bn. The group is tackling the challenge of rising import costs by bulk procurement of medical equipment, consumables, and generic medications, highlighted the news agency. This strategy aims to reduce the financial burden of imported goods, according to Nair. In China, IHH is focusing on solidifying its presence. The company has transitioned its clinic business into a profitable venture and is witnessing an increase in patient numbers at its Shanghai hospital. Despite China easing foreign investment restrictions in the healthcare sector, IHH remains cautious about further expansion, given the strong competition from the public sector, as further outlined by Bloomberg. Nair said: 'In China, the public sector is a very big competitor to private healthcare. 'We are the only foreign operator in China who has a combination of clinics, and an ecosystem, so we will build on it.' The company's growth plans are not limited to new markets. It also intends to increase hospital bed capacity by 33% from 2024 through 2028 in existing markets, adding 4,000 beds. For the first quarter, IHH reported a revenue of MYR6.29bn ($1.48bn), a 5.7% rise from the previous year. However, its profit dropped 33% to MYR514m, due to exceptional accounting adjustments. While Turkey, Singapore, and Malaysia are the current primary revenue sources, the company anticipates India to become a significant contributor due to the growing demand for private healthcare. Nair emphasised the importance of developing out-of-hospital care, such as ambulatory surgical and care centres, to mitigate cost pressures. IHH operates 60 such non-hospital healthcare facilities. While Singapore has established a comprehensive ecosystem and Hong Kong is progressing towards one, Malaysia's regulations currently prevent hospital operators from managing other healthcare facilities. IHH plans to appeal to Malaysia's Health Ministry to change this rule, hoping to expand significantly into the out-of-hospital sector. "IHH Healthcare pursues expansion in Indonesia and Vietnam" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Upturn
30-06-2025
- Business Upturn
Biocon Biologics crosses 100 million insulin cartridge deliveries in Malaysia
By Aman Shukla Published on June 30, 2025, 08:56 IST Biocon Biologics Ltd. (BBL), through its Malaysian arm Biocon Sdn. Bhd., has delivered over 100 million cartridges of recombinant human insulin (rh-insulin) to Malaysia's Ministry of Health (MoH). The company has been supplying insulin to Malaysia since 2016, supporting diabetes management efforts across the country. As part of a long-standing public-private partnership with the Malaysian government, Biocon Biologics has helped serve around 345,000 patients by making rh-insulin more accessible. The collaboration is aimed at supporting local healthcare needs through stable supply and improved access to affordable insulin therapy. The company's insulin manufacturing facility in Johor, established with a cumulative investment of $600 million since 2011, functions as a Center of Excellence (CoE) for insulin production. The facility is equipped to manufacture various types of insulin—regular, basal, and rapid-acting—in formats such as cartridges and delivery devices. The site has been acknowledged by the Malaysia Book of Records as the country's first and largest integrated insulin manufacturer. Globally, Biocon Biologics has distributed over 9.2 billion doses of rh-Insulin and Insulin Glargine to patients, as part of its wider effort to support insulin access worldwide. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at

26-06-2025
An Alaskan brown bear has a new shiny smile after getting a huge metal crown for a canine tooth
DULUTH, Minn. -- An Alaskan brown bear at the Lake Superior Zoo in northeastern Minnesota has a gleaming new silver-colored canine tooth in a first-of-its-kind procedure for a bear. The 800-pound (360-kilogram) Tundra was put under sedation Monday and fitted with a new crown — the largest dental crown ever created, according to the zoo. 'He's got a little glint in his smile now,' zoo marketing manager Caroline Routley said Wednesday. The hour-long procedure was done by Dr. Grace Brown, a board-certified veterinary dentist who helped perform a root canal on the same tooth two years ago. When Tundra reinjured the tooth, the decision was made to give him a new, stronger crown. The titanium alloy crown, made by Creature Crowns of Post Falls, Idaho, was created for Tundra from a wax caste of the tooth. Brown plans to publish a paper on the procedure in the Journal of Veterinary Dentistry later this year. 'This is the largest crown ever created in the world," she said. 'It has to be published.' Tundra and his sibling, Banks, have been at the Duluth zoo since they were 3 months old, after their mother was killed. Tundra is now 6 years old and, at his full height on his hind legs, stands about 8 feet (2.4 meters) tall. The sheer size of the bear required a member of the zoo's trained armed response team to be present in the room — a gun within arm's reach — in case the animal awoke during the procedure, Routley said. But the procedure went without a hitch, and Tundra is now back in his habitat, behaving and eating normally. Other veterinary teams have not always been as lucky. In 2009, a zoo veterinarian at Henry Doorly Zoo and Aquarium in Omaha, Nebraska, suffered severe injuries to his arm while performing a routine medical exam on a 200-pound (90 kilogram) Malaysian tiger. The tiger was coming out of sedation when the vet inadvertently brushed its whiskers, causing the tiger to reflexively bite down on the vet's forearm.